Automate Your Wheel Strategy on OPRX
With Tiblio's Option Bot, you can configure your own wheel strategy including OPRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OPRX
- Rev/Share 5.1089
- Book/Share 6.2948
- PB 2.0874
- Debt/Equity 0.2821
- CurrentRatio 2.8179
- ROIC -0.0675
- MktCap 243025614.0
- FreeCF/Share 0.3417
- PFCF 38.5083
- PE -15.752
- Debt/Assets 0.1955
- DivYield 0
- ROE -0.1315
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | OPRX | RBC Capital Mkts | Outperform | Sector Perform | $7 | $6 | Jan. 8, 2025 |
| Initiation | OPRX | Stephens | -- | Equal Weight | -- | $5.5 | Dec. 20, 2024 |
News
Does OptimizeRx Have a Moat in the Crowded HealthTech Space?
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral
OptimizeRx OPRX is carving out a secure niche in the increasingly crowded HealthTech landscape, signaling a developing moat anchored in scale, data and execution. Over the previous two quarters, the company has posted double-digit top-line growth.
Read More
OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.
Read More
Best Growth Stocks to Buy for July 22nd
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
OPRX, ADRNY and DELL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 22, 2025.
Read More
OptimizeRx: Stock Could Rise As Profitability Is Achieved
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
I expect OptimizeRx to turn profitable in 2025, driven by strong double-digit revenue growth and reduced operating expenses. The company's proprietary AI-powered omnichannel platform connects over 2 million healthcare providers with millions of patients, enabling effective targeted marketing. OPRX's unique Dynamic Audience Activation Platform and Micro-Neighborhood Targeting differentiate it from competitors and support its patient-centered strategy.
Read More
Can OPRX's Patient Engagement Tools Win Amid Fierce Competition?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
OptimizeRx bets on EHR-linked messaging and geo-targeting to stand out, but scaling in a crowded digital health field remains key.
Read More
OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call.
Read More
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
OPRX is growing faster with rising subscription revenues and strong pharma demand, while GDRX lags due to slower consumer growth.
Read More
OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.
Read More
Best Growth Stocks to Buy for July 9th
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
OPRX, EWCZ and QFIN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 9, 2025.
Read More
Can OptimizeRx Maintain Profit Growth Amid Evolving Pharma Spend?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
OPRX raised guidance after record Q1 EBITDA, but pharma budget shifts and margin mix pose new challenges ahead.
Read More
OPRX Shares Rise 69.3% in 3 Months: Time to Bet on the Stock?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
OPRX surged 69.3% in three months as rising contracted revenue and subscription gains boost confidence and guidance.
Read More
Here's Why OptimizeRx Corp. (OPRX) is a Great Momentum Stock to Buy
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Does OptimizeRx Corp. (OPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Earnings Estimates Rising for OptimizeRx (OPRX): Will It Gain?
Published: May 22, 2025 by: Zacks Investment Research
Sentiment: Positive
OptimizeRx (OPRX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
OptimizeRx to Participate in Upcoming Investor Conferences
Published: May 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., May 16, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences:
Read More
OptimizeRx Corporation (OPRX) Q4 2024 Earnings Call Transcript
Published: March 12, 2025 by: Seeking Alpha
Sentiment: Neutral
OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2024 Results Conference Call March 12, 2025 8:30 AM ET Company Participants Steve Silvestro - President Edward Stelmakh - Chief Financial Officer and Chief Operational Officer Andrew D'Silva - Senior Vice President of Corporate Finance Conference Call Participants Jared Haase - William Blair Anderson Schock - B. Riley Constantine Davides - Citizens JMP Richard Baldry - ROTH Capital David Grossman - Stifel Financial Eric Martinuzzi - Lake Street Jeff Garro - Stephens, Inc Operator Good morning, everyone, and thank you for joining OptimizeRx's Fourth Quarter and Full Year Fiscal 2024 Earnings Conference Call.
Read More
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.26 per share a year ago.
Read More
About OptimizeRx Corporation (OPRX)
- IPO Date 2007-11-28
- Website https://www.optimizerx.com
- Industry Medical - Healthcare Information Services
- CEO Stephen L. Silvestro
- Employees 128